“Mitigative Efficacy of the Clinical Dosage Administration of Granulocyte Colony-Stimulating Factor”

High-exposure irradiation has been a topic for continuous research in terms of defining ways to mitigate the destructive effect of radiation on the human body. A major segment of these studies is dedicated to the issue of total-body irradiation (TBI), which results in acute effects on the hematopoietic system leading to a fatal outcome. Yamaguchi et al. (2020) attempted to discover whether the administration of granulocyte colony-stimulating factor (G-SCF) and romiplostim (RP) positively affects the process of immediate TBI treatment. Thus, the primary goal of the research was to calculate to which extent the aforementioned treatment of acute radiation syndrome could be influenced based on animal experiments’ conduction.

The methodology of the study included the following aspects:

  • The collection of the study participants, including seven-week-old mice, which were supposed to undergo seven days of acclimatization to the environment;
  • Mice’s exposure to TBI by administrating various dosages of X-rays;
  • Drug administration of G-CSF and RP within two hours after the TBI, conducted in four different administration combinations, lasting for 21 days;
  • Cell collection and analysis;
  • Assessment of the statistical data with the help of ANOVA and ELISA analyses (Yamaguchi et al., 2020).

The interpretation of the results of the study was primarily aimed at calculating the survival rate of the participants once the clinical dosage administration and G-SCF/RP treatment are combined within the rehabilitation process. Thus, the findings have shown that such an approach to the TBI treatment contributed to the improvement of the 30-day survival rate, along with the increasing of hematopoietic cells in the participants’ organism. (Yamaguchi et al., 2020). The researchers have concluded that the following treatment process benefits the overall radiation mitigating effect and poses as a strong therapeutic tool for the rehabilitation process. The future implications of the study might concern the studies related to the direct treatment effect on radiation-exposed humans.

Reference

Yamaguchi, M., Suzuki, M., Funaba, M., Chiba, A., & Kashiwakura, I. (2020). Mitigative efficacy of the clinical dosage administration of granulocyte colony-stimulating factor and romiplostim in mice with severe acute radiation syndrome. Stem Cell Research & Therapy, 11(339), 1-16. Web.

Cite this paper

Select style

Reference

NursingBird. (2022, March 9). “Mitigative Efficacy of the Clinical Dosage Administration of Granulocyte Colony-Stimulating Factor”. https://nursingbird.com/mitigative-efficacy-of-the-clinical-dosage-administration-of-granulocyte-colony-stimulating-factor/

Work Cited

"Mitigative Efficacy of the Clinical Dosage Administration of Granulocyte Colony-Stimulating Factor." NursingBird, 9 Mar. 2022, nursingbird.com/mitigative-efficacy-of-the-clinical-dosage-administration-of-granulocyte-colony-stimulating-factor/.

References

NursingBird. (2022) '“Mitigative Efficacy of the Clinical Dosage Administration of Granulocyte Colony-Stimulating Factor”'. 9 March.

References

NursingBird. 2022. "Mitigative Efficacy of the Clinical Dosage Administration of Granulocyte Colony-Stimulating Factor." March 9, 2022. https://nursingbird.com/mitigative-efficacy-of-the-clinical-dosage-administration-of-granulocyte-colony-stimulating-factor/.

1. NursingBird. "Mitigative Efficacy of the Clinical Dosage Administration of Granulocyte Colony-Stimulating Factor." March 9, 2022. https://nursingbird.com/mitigative-efficacy-of-the-clinical-dosage-administration-of-granulocyte-colony-stimulating-factor/.


Bibliography


NursingBird. "Mitigative Efficacy of the Clinical Dosage Administration of Granulocyte Colony-Stimulating Factor." March 9, 2022. https://nursingbird.com/mitigative-efficacy-of-the-clinical-dosage-administration-of-granulocyte-colony-stimulating-factor/.